- Home
- BELFB vs MNKD Comparison
BELFB vs MNKD Comparison
Compare BELFB & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BELFB
- MNKD
- Stock Information
- Founded
- BELFB 1949
- MNKD 1991
- Country
- BELFB United States
- MNKD United States
- Employees
- BELFB N/A
- MNKD N/A
- Industry
- BELFB
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- BELFB
- MNKD Health Care
- Exchange
- BELFB Nasdaq
- MNKD Nasdaq
- Market Cap
- BELFB 1.8B
- MNKD 1.7B
- IPO Year
- BELFB N/A
- MNKD 2004
- Fundamental
- Price
- BELFB $147.67
- MNKD $5.18
- Analyst Decision
- BELFB Strong Buy
- MNKD Strong Buy
- Analyst Count
- BELFB 4
- MNKD 5
- Target Price
- BELFB $142.25
- MNKD $10.80
- AVG Volume (30 Days)
- BELFB 116.0K
- MNKD 3.9M
- Earning Date
- BELFB 10-22-2025
- MNKD 11-06-2025
- Dividend Yield
- BELFB 0.19%
- MNKD N/A
- EPS Growth
- BELFB N/A
- MNKD 149.32
- EPS
- BELFB 4.05
- MNKD 0.11
- Revenue
- BELFB $594,034,000.00
- MNKD $301,736,000.00
- Revenue This Year
- BELFB $25.48
- MNKD $16.36
- Revenue Next Year
- BELFB $5.57
- MNKD $20.34
- P/E Ratio
- BELFB $36.23
- MNKD $50.23
- Revenue Growth
- BELFB 6.08
- MNKD 21.48
- 52 Week Low
- BELFB $58.00
- MNKD $3.38
- 52 Week High
- BELFB $152.45
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- BELFB 58.95
- MNKD 46.75
- Support Level
- BELFB $138.32
- MNKD $5.33
- Resistance Level
- BELFB $149.01
- MNKD $5.90
- Average True Range (ATR)
- BELFB 6.07
- MNKD 0.24
- MACD
- BELFB -0.34
- MNKD -0.06
- Stochastic Oscillator
- BELFB 83.83
- MNKD 5.88
About BELFB Bel Fuse Inc. Class B
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.